California is currently home to 5585 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469
Recruiting
Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS) and lower risk chronic my... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/26/2025
Locations: Stanford Cancer Center, Stanford, California
Conditions: Myeloid Diseases
Register for Updates
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798
Recruiting
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the adva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: Los Angeles Hematology Oncology Medical Group, Los Angeles, California
Conditions: Locally Advanced or Metastatic Breast Cancer
Register for Updates
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/26/2025
Locations: City of Hope, Duarte, California
Conditions: Multiple Myeloma
Register for Updates
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559
Recruiting
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use. Participants will have to inject the study medicine every day under the skin with a pen-injector. The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for pur... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/26/2025
Locations: Rady Childrens Hosp San Diego, San Diego, California
Conditions: Haemophilia A and B With and Without Inhibitors
Register for Updates
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
NCT05035030
Recruiting
The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS). The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membran... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/26/2025
Locations: UCSF, San Francisco, California
Conditions: Alagille Syndrome
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
05/25/2025
Locations: Division of Endocrinology, Diabetes, and Metabolism, Los Angeles, California
Conditions: Type 2 Diabetes
Register for Updates
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045
Recruiting
Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at ti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/25/2025
Locations: Ark Clinical Research, Long Beach, California
Conditions: OSA, Overweight or Obesity
Register for Updates
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
NCT06606106
Recruiting
This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031 in participants who are overweight and obese. Part B and Part C will study the safety and tolerability of LY3537031 in healthy participants. Part C will contain only Japanese and Chinese healthy participants. Blood tests will be performed to check how much LY3537031 gets into the bloodstream and how long it takes the body to eliminate it. Body wei... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
05/25/2025
Locations: Collaborative Neuroscience Research, LLC, Los Alamitos, California
Conditions: Healthy, Obesity
Register for Updates
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277
Recruiting
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/25/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California
Conditions: Obesity, Weight Gain
Register for Updates
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
NCT06167733
Recruiting
Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment. Baseline assessments will include collection of demographic data, medical history, concomitant medications and baseline clinical examinations. The initial treatment session will be performed in a clinical setting simulating home use to determine proper device use and to... Read More
Gender:
MALE
Ages:
Between 22 years and 85 years
Trial Updated:
05/25/2025
Locations: University of California, Irvine Medical Center, Newport Beach, California
Conditions: Erectile Dysfunction
Register for Updates
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
NCT05669664
Recruiting
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/24/2025
Locations: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
Conditions: Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Register for Updates
A Study Assessing KB801 for the Treatment of Stage 2 or 3 Neurotrophic Keratitis
NCT06999733
Recruiting
The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via topical application. This is a Phase 1/2, multicenter, double-masked, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of KB801 in these subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of California Irvine, Irvine, California
Conditions: Neurotrophic Keratitis
Register for Updates